Biotech
$VNRX
VolitionRx Limited
A first half update: revenue of $1.4 million, up 112% year on year, the Nu.Q NETs assay transferred onto Sysmex's platform, and licensing discussions running with more than a dozen diagnostics and liquid biopsy companies.
Get started
Don't wait.
Let's stack the odds in your favor. Book a discovery call and we will put together a plan around your catalyst calendar.
Get a tailor-made game plan just for you.
30 minutes. Bring your catalyst calendar and we will tell you how we would cover it.